BENEFICIAL-EFFECTS OF THE CALCIUM-ANTAGONIST ISRADIPINE ON APOLIPOPROTEINS IN HYPERTENSIVE PATIENTS

被引：7

作者：

LACOURCIERE, Y

GAGNE, C

BRUN, D

POIRIER, L

DION, D

YARDLEY, C

机构：

[1] Units of Hypertension Research and Lipid Research, Le Centre Hospitalier de l'Universite Laval, Sainte-Foy, QC

[2] Research Unit (Room S-135), Le Centre Hospitalier de l'Universite Laval, Sainte-Foy, QC, G1V 4G2, 2705, boulevard Laurier

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1991年 / 4卷 / 02期

关键词：

ISRADIPINE; APOLIPOPROTEINS; HYPERTENSION;

D O I：

10.1093/ajh/4.2.181S

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

The objective of the study was to assess the effects of the calcium antagonist isradipine on plasma lipids, lipoproteins, and apolipoproteins in patients with essential hypertension. After a four-week placebo wash-out period, 73 patients (41 men, 32 women) were studied in a double-blind, randomized, crossover study comparing sustained-release isradipine (isradipine SR) with the standard isradipine formulation. Nineteen patients received 5 mg/day and 54 patients 10 mg/day. Lipids were evaluated at the end of the placebo period and after 12 weeks of treatment with isradipine. In both treatment groups, lipid and lipoproteins were not modified. However, apolipoprotein A-I levels increased significantly (P < .001) and the ratio of apolipoprotein B to apolipoprotein A-I concentration decreased significantly (P < .01) irrespective of gender. These data show that the levels of plasma apolipoprotein A-I, a strong predictor of coronary heart disease, are favorably affected by isradipine of either formulation. The mechanisms of this effect remain to be elucidated.

引用

页码：S181 / S184

页数：4

共 20 条

[1]

Macmahon S.W., Cutler J.A., Furberg C.D., The effectsof drug treatment for hypertension on morbidity andmortality from cardiovascular disease: A review of randomized, controlled trials, Prog Cardiovasc Dis, 29, (1986)

[2]

Ames R.P., Antihypertensive drugs and lipid profiles, AmJ Hypertens, 1, pp. 421-427, (1988)

[3]

Lacourciere Y., Gagne C., Bielman P., Et al., Influence ofpropranolol and metoprolol on plasma lipoproteins innormolipidemic subjects, Curr Ther Res, 39, pp. 1033-1043, (1986)

[4]

Kannel W.B., Carter B.L., Initial drug therapy for hypertensive patients with hyperlipidemia, Am Heart J, 118, pp. 1012-1020, (1989)

[5]

Lacourciere Y., Gagne C., Influence of zofenopril and lowdoses of hydrochlorothiazide on plasma lipoproteins inpatients with mild to moderate essential hypertension, Am J Hypertens, 2, pp. 862-864, (1989)

[6]

Wada R.P., Satoh K., Taira N., A study on the separation ofcoronary vasodilator from cardiac effects of PN 200-110, a new dihydropyridine calcium antagonist, in the dogheart, J Cardiovasc Pharmacol, 7, pp. 190-196, (1985)

[7]

Hamilton B.P., Treatment of essential hypertension withPN 200-110 (Isradipine), Am J Cardiol, 59, pp. 141B-145B, (1987)

[8]

Multicenterevaluation of the safety and efficacy of isradipine in hypertension, Am J Med, 86, pp. 94-97, (1989)

[9]

A multicenterevaluation of safety and efficacy of isradipine and atenolol in the treatment of hypertension, Am J Med, 86, pp. 119-123, (1989)

[10]

Rauramaa R., Taskinen E., Seppanen K., Effects of calcium antagonist treatment on blood pressure, lipoproteins, and prostaglandins, Am J Med, 84, pp. 93-96, (1988)

← 1 2 →